Atara, Pierre Fabre hit a hurdle with Ebvallo in the US courtesy of manufacturing plant's shortfalls
Then in 2023, Pierre Fabre took on the drug's U.S. rights in a deal worth up to $640 million. Related In deal worth up to $640M, Pierre Fabre doubles down on its T-cell partnership with Atara ...
The three-drug regimen – based on Array BioPharma/Pierre Fabre’s BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib) along with Eli Lilly’s EGFR-targeted antibody E ...
Hosted on MSN1mon
Here's Why You Should Consider Buying Atara Biotherapeutics StockDeal With Pierre Fabre Strengthens ATRA's Cash Position Tab-cel is already marketed in the EU under the brand name, Ebvallo, by Atara’s partner Pierre Fabre Medicament under an exclusive ...
“We are working closely with our partner Pierre Fabre Laboratories, the FDA, and the third-party manufacturer to address the feedback to support marketing approval for EBVALLO,” said Cokey ...
Jubilant Biosys Innovative Research Services, Singapore (JBIRSPL), a subsidiary of Jubilant Biosys, a wholly owned subsidiary of Jubilant Pharmova, has executed the transaction definitive agreements ...
To solve the FDA-identified problems, Atara stated it is collaborating with third-party manufacturer and partner Pierre Fabre Laboratories. With a possible approval period of six months after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback